The present invention discloses methods for therapeutically treating mammals,
including but not limited to humans, to increase the relative insulin producing
performance of endogenous pancreatic -cells, to cause differentiation of
pancreatic epithelial cells into insulin producing -cells, to improve muscle
sensitivity to insulin and other weight control efforts by the chronic oral administration
of a DP IV-inhibitor. The administration causes the active form of GLP-1 and other
non-nutrient stimulated growth hormones to remain biologically active longer under
physiological conditions. The extended presence of such hormones, in particular
in the pancreatic tissue can also facilitate differentiation and regeneration of
the -cells already present that are in need of repair.
